Neurotrophic factors as a therapeutic target for Parkinson's disease

Bibliography

• Yuen EC, Mobly WC. Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol 1996;40:346-54
   PubMed Web of Science ®Google Scholar
• Siegel GJ, Chauhan NB. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res Rev 2000;33:199-227
   PubMedGoogle Scholar
• Ebadi M, Bahir RM, Heidrick FM, et al. Neurotrophins and their receptors in nerve injury and repair. Neurochem Int 1997;30:465-74
   PubMedGoogle Scholar
• Zaccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007;81:294-330
   PubMedGoogle Scholar
• How many people have Parkinson's disease? Parkinson's disease society of the United Kingdom. Available from: www.parkinsons.org.uk/about-parkinsons what-is-parkinsons/how-many-people-have-parkinson.aspx [Last accessed 30 November 2007]
   Google Scholar
• Schapira AH. Treatment options in the modern management of Parkinson's disease. Arch Neurol 2007;64:1083-8
   PubMedGoogle Scholar
• Lin L-F, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-2
   PubMedGoogle Scholar
• Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on the survival and function of midbrain dopaminergic neurons. J Neurosci 1998;18:4929-37
   PubMedGoogle Scholar
• Milbrandt J, de Sauvage FJ, Fahrner TJ, et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 1998;20:245-53
   PubMedGoogle Scholar
• Baloh RH, Tansey MG, Lampe PA, et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRα3-RET receptor complex. Neuron 1998;21:1291-302
   PubMedGoogle Scholar
• Gardell LR, Wang R, Ehrenfels C, et al. Multiple actions of systemic artemin in experimental neuropathy. Nat Med 2003;9:1383-9
   PubMedGoogle Scholar
• Durbec P, Marcos-Guiterrez CV, Kilkenny C, et al. GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996;381:789-93
   PubMedGoogle Scholar
• Trupp M, Belluardo N, Funakoshi H, Ibanez CF. Complementary and overlapping expression of glial cell line-derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-α indicates multiple mechanisms of trophic actions in the adult rat CNS. J Neurosci 1997;17:3554-67
   PubMedGoogle Scholar
• Naveilhan P, Baudet C, Mikaels A, et al. Expression and regulation of GFR α3, a glial cell line-derived neurotrophic family receptor. Proc Natl Acad Sci 1998;95:1295-300
   PubMedGoogle Scholar
• Trupp M, Raynoshenk C, Bellurado N, Ibanez CF. Multiple GPI-anchored receptors control GDNF-dependentand independent activation of the c-Ret receptor tyrosine kinase. Mol Cell Neurosci 1998;11:47-63
   PubMedGoogle Scholar
• Chauhan NB, Lee JM, Siegel GJ. Selective depletion of glial cell line-derived neurotrophic factor (GDNF) in Parkinson's disease. Neurology 1999;52:A212-3
   Google Scholar
• Hyman C, Hoffer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991;350:230-2
   PubMedGoogle Scholar
• Knusel B, Michel PP, Schwaber JS, et al. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J Neurosci 1990;10:558-70
   PubMedGoogle Scholar
• Frim DM, Uhler TA, Kern WR, Beal MF. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons. Proc Natl Acad Sci 1994;91:5104-8
   PubMedGoogle Scholar
• Bowers WJ, Howard DF, Federoff HJ. Gene therapeutic strategies for neuroprotection: Implications for Parkinson's disease. Exp Neurol 1997;144:58-68
   PubMedGoogle Scholar
• Sun M, Kong l, Wang X, et al. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 2005;1052:119-29
   PubMedGoogle Scholar
• Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J 2006;6:8-15
   PubMedGoogle Scholar
• Foltynie T, Lewis SG, Goldberg TE, et al. The BDNF Val66Met polymorphism has a gender specific influence upon planning ability in Parkinson's disease. J Neurol 2005;252:833-8
   PubMedGoogle Scholar
• Kuipers SD, Bramham CR. Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Dev 2006;9:580-6
   PubMedGoogle Scholar
• Cass WA, Peters LE, Hamed ME, Seroogy KB. Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine. Ann NY Acad Sci 2006;1074:272-81
   PubMedGoogle Scholar
• Bloch J, Bachoud-Lévi AC, Déglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004;15:968-75
   PubMedGoogle Scholar
• Ahlskog JE. Challenging conventional wisdom: the etiological role of dopamine oxidative stress in Parkinson's disease. Mov Disord 2005;20:271-82
   PubMedGoogle Scholar
• Lindholm P, Voutilainen MH, Lauren J, et al. Novel neurotrophic factor CDNF protects and rescues dopamine neurons in vivo. Nature 2007;448:73-7
   PubMedGoogle Scholar
• Hirsch EC. Animal models in neurodegenerative diseases. J Neural Trans Suppl 2007;72:87-90
   PubMedGoogle Scholar
• Soderstrom K, O'Malley J, Steece-Kollier K, Kordower JH. Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant 2006;15:251-65
   PubMedGoogle Scholar
• Kirik D, Georgievska B, Rosenblad C, Bjorklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci 2001;13:1589-99
   PubMedGoogle Scholar
• Aoi M, Date I, Tomita S, Ohmoto T. Single or continuous injection of glial cell line-derived neurotrophic factor in the striatum induces recovery of the nigrostriatal dopaminergic system. Neurol Res 2000;22:832-6
   PubMedGoogle Scholar
• Aoi M, Date I, Tomita S, Ohmoto T. GDNF induces recovery of the nigrostriatal system in the rat brain following intracerebroventricular or intraparenchymal administration. Acta Neurochir 2000;142:805-10
   PubMedGoogle Scholar
• Yasuhara T, Shingo T, Muraoka K, et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson's disease. J Neurosurg 2005;102:80-9
   PubMedGoogle Scholar
• Emerich DF, Winn SR, Christenson L, et al. A novel approach to neural transplantation in Parkinson's disease: use of polymer-encapsulated cell therapy. Neurosci Biobehav Rev 1992;16:437-47
   PubMedGoogle Scholar
• Yasuhara T, Shingo T, Date I. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease. Acta Med Okayama 2007;61:51-6
   PubMedGoogle Scholar
• Arjona V, Minguez-Castellanos A, Montoro RJ, et al. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 2003;53:321-8
   PubMedGoogle Scholar
• Tatard VM, Sinji L, Branton JG, et al. Pharmacologically active microcarriers releasing glial cell line-derived neurotrophic factor: survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats. Biomaterials 2007;28:1978-88
   PubMedGoogle Scholar
• Kordower JH. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann Neurol 2003;53(Suppl 3):S120-34
   Google Scholar
• Bjorklund A, Kirik D, Rosenblad C, et al. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinsonian model. Brain Res 2000;886:82-98
   PubMedGoogle Scholar
• Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997;275:838-41
   PubMedGoogle Scholar
• Kirik D, Rosenblad C, Bjorklund A, Mandel RI. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000;20:4686-700
   PubMedGoogle Scholar
• Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000;164:2-14
   PubMedGoogle Scholar
• Gasmi M, Herzog CD, Brandon EP, et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 2007;15(1):62-8
   PubMedGoogle Scholar
• Schnepp BC, Clark KR, Klemanski DL, et al. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003;77:3495-504
   PubMedGoogle Scholar
• Kordower JH, Emberg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290:767-73
   PubMedGoogle Scholar
• Zhang Z, Miyoshi Y, Lapchak PA, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997;282:1396-401
   PubMedGoogle Scholar
• Georgievska B, Kirik D, Björklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci 2004;21:6437-45
   PubMedGoogle Scholar
• Chtarto A, Yanq X, Bockstael O, et al. Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. Exp Neurol 2007;204:387-99
   PubMedGoogle Scholar
• Nutt JG, Burchel KJ, Comella CL, et al. Randomised, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2002;60:69-73
   Google Scholar
• Kish SJ, Shannack K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-80
   PubMedGoogle Scholar
• Gill SS, Patel, NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson's disease. Nat Med 2003;9:589-94
   PubMedGoogle Scholar
• Morrish PK, Sawle GV, Brooks DJ. An 18F-dopa-PET and clinical study of the rate of progression of Parkinson's disease. Brain 1996;119:585-91
   PubMedGoogle Scholar
• Patel NK, Bunnage M, Plaha P, et al. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two year outcome study. Ann Neurol 2005;57:298-302
   PubMedGoogle Scholar
• Bhatia KP, Marsden CD. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994;117:859-76
   PubMedGoogle Scholar
• Patel NK, Gill SS. GDNF delivery for Parkinson's disease. Acta Neurochir Suppl 2007;97:135-54
   PubMedGoogle Scholar
• Slevin JT, Gerhardt GA, Smith CD, et al. Improvement of bilateral motor functions in patients with Parkinson's disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005;102:216-22
   PubMedGoogle Scholar
• Lindvall O, Widner H, Rehncrona S, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992;31:155-65
   PubMedGoogle Scholar
• Lindvall O, Sawle G, Widner H, et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Ann Neurol 1994;35:172-80
   PubMedGoogle Scholar
• Slevin JT, Gash DM, Smith CD, et al. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson's disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 2007;106:614-20
   PubMedGoogle Scholar
• Lang AE, Gill SS, Patel NK, et al. Randomised controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson's disease. Ann Neurol 2006;59:459-66
   PubMedGoogle Scholar
• Hutchinson M, Gurney S, Newson R. GDNF in Parkinson's disease: an object lesson in the tyranny of type II. J Neurosci Methods 2007;163:190-2
   PubMedGoogle Scholar
• Matcham J, McDermott MP, Lang AE. GDNF in Parkinson's disease: the perils of post-hoc power. J Neurosci Methods 2007;163:193-6
   PubMedGoogle Scholar
• Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-9
   PubMedGoogle Scholar
• Barker RA. Continuing trials of GDNF in Parkinson's disease. Lancet Neurol 2006;5:285-6
   PubMedGoogle Scholar
• Sherer TB, Fiske BK, Svendsen CN, et al. Crossroads in GDNF therapy for Parkinson's disease. Mov Disord 2006;21:136-41
   PubMedGoogle Scholar
• Goetz CG, Janko K, Blasucci L, et al. Impact of placebo assignment in clinical trials of Parkinson's disease. Mov Disord 2003;18:1146-9
   PubMedGoogle Scholar
• De la Fuente-Fernandez R, Schulzer M, Stoessl AJ. Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry 2004;15:67-71
   PubMedGoogle Scholar
• Peck P. Amgen decision to halt GDNF clinical trials and withdraw the drug triggers protest from researchers and patients. Neurol Today Am Acad Neurol 2005;5:4
   Google Scholar
• Lang AE, Langston WJ, Stoessl AJ, et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 2006;5:200-2
   PubMedGoogle Scholar
• Penn RD, Dalvi A, Slevin J, et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 2006;5:202-3
   PubMedGoogle Scholar
• Marks WJ Jr, Verhagen L, Starr P et al. Phase I study of putaminal gene transfer with adeno-associated virus serotype 2 [AAV2]-Neurturin [NTN] (CERE-120) for Parkinson's disease. American Academy of Neurology 58th Annual Meeting; San Diego, CA, USA; 2006;66(5 Suppl 2):Abstract S23.006
   Google Scholar
• Starr PA, Verhagen L, Larson PS, et al. Intrastriatal gene transfer with AAV-neurturin for Parkinson's disease: results of a phase I trial. American Association of Neurosurgeons 75th Annual Meeting; Washington, DC, USA; 2007;Abstract 402
   Google Scholar
• Kaplitt MG, Feigin A, Tang C, et al. Safety and tolerability of a gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-105
   PubMedGoogle Scholar
• Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. TIPS 2007;28:68-74
   PubMedGoogle Scholar
• Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-12
   PubMedGoogle Scholar
• Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-16
   PubMedGoogle Scholar
• Williams-Gray CH, Foltynie T, Brayne CEG, et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130:1787-98
   PubMedGoogle Scholar
• Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's Disease. Ann Neurol 2007;62:145-53
   PubMedGoogle Scholar
• Akerud P, Holm PC, Castelo-Branco G. Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease. Mol Cell Neurosci 2002;21:205-22
   PubMedGoogle Scholar
• Olson L, Backlund EO, Ebendal T, et al. Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease. One-year follow-up of first clinical trial. Arch Neurol 1991;48:373-81
   PubMedGoogle Scholar
• Hyman C, Juhasz M, Jackson C, et al. Overlapping and distinct actions of the neurotrophins, BDNF, NT3 and NT4/5, on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci 1994;14:335-47
   PubMedGoogle Scholar
• Haque NS, Hlavin ML, Fawcett JW, et al. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease. Brain Res 1996;712:45-52
   PubMedGoogle Scholar
• Pennica D, Shaw KJ, Swanson TA, et al. Cardiotrophin-1. Biological activities and binding to the leukemia inhibitory factor receptor/gp130 signaling complex. J Biol Chem 1995;270:10915-22
   PubMedGoogle Scholar
• Howells DW, Wong JY, Churchyard AJ, et al. Leukaemia inhibitory factor prevents injury induced proliferation of striatal dopamine uptake sites. Neuroreport 1995;6:1857-60
   PubMedGoogle Scholar
• Engele J. Changing responsiveness of developing midbrain dopaminergic neurons for extracellular growth factors. J Neurosci Res 1998;51:508-16
   PubMedGoogle Scholar
• Casper D, Blum M. Epidermal growth factor and basic fibroblast growth factor protect dopaminergic neurons from glutamate toxicity in culture. J Neurochem 1995;65:1016-26
   PubMedGoogle Scholar
• Petrova P, Raibekas A, Pevsner J, et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 2003;20:173-88
   PubMedGoogle Scholar